Search

Ann Raddant Phones & Addresses

  • Muskego, WI
  • Iowa City, IA
  • Indian Trail, NC
  • Wingate, NC

Work

Company: University of wisconsin milwaukee Aug 2017 Position: Lecturer

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Iowa 2008 to 2013 Specialities: Biophysics, Physiology, Philosophy

Skills

Western Blotting • Cell Culture • Pcr • Molecular Biology • Confocal Microscopy • Fluorescence Microscopy • Molecular Cloning • Microscopy • Immunohistochemistry • Tissue Culture • Elisa • Rt Pcr • Qpcr • Protein Expression

Interests

Animal Welfare

Industries

Higher Education

Resumes

Resumes

Ann Raddant Photo 1

Lecturer

View page
Location:
Iowa City, IA
Industry:
Higher Education
Work:
University of Wisconsin Milwaukee
Lecturer

St. Ambrose University Jan 2014 - May 2017
Assistant Professor of Biology

University of Iowa Jun 2008 - Dec 2013
Graduate Research Assistant

Wingate University Sep 2005 - Dec 2007
Peer Tutor

Wixon May 2006 - Aug 2006
Quality Control Technician
Education:
University of Iowa 2008 - 2013
Doctorates, Doctor of Philosophy, Biophysics, Physiology, Philosophy
Wingate University 2004 - 2007
Bachelors, Bachelor of Science, Biology
Skills:
Western Blotting
Cell Culture
Pcr
Molecular Biology
Confocal Microscopy
Fluorescence Microscopy
Molecular Cloning
Microscopy
Immunohistochemistry
Tissue Culture
Elisa
Rt Pcr
Qpcr
Protein Expression
Interests:
Animal Welfare

Publications

Us Patents

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels

View page
US Patent:
20120294822, Nov 22, 2012
Filed:
May 21, 2012
Appl. No.:
13/476104
Inventors:
Andrew F. Russo - Iowa City IA, US
Eric A. Kaiser - Iowa City IA, US
Ana Recober - Iowa City IA, US
Adisa Kuburas - North Liberty IA, US
Ann C. Raddant - Iowa City IA, US
Brian Robert Kovacevich - Snohomish WA, US
John A. Latham - Seattle WA, US
Jeffrey T.L. Smith - Bellevue WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
International Classification:
A61K 39/395
A61P 1/12
A61K 31/785
US Classification:
424 7801, 4241581, 4241331, 4241351
Abstract:
The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers

View page
US Patent:
20120294802, Nov 22, 2012
Filed:
May 21, 2012
Appl. No.:
13/476632
Inventors:
Andrew F. Russo - Iowa City IA, US
Eric A. Kaiser - Iowa City IA, US
Ana Recober - Iowa City IA, US
Adisa Kuburas - North Liberty IA, US
Ann C. Raddant - Iowa City IA, US
Brian Robert Kovacevich - Snohomish WA, US
John A. Latham - Seattle WA, US
Jeffrey T.L. Smith - Bellevue WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
International Classification:
A61K 39/395
A61K 51/10
A61P 25/06
A61P 25/00
A61P 27/02
A61P 27/12
A61P 13/00
A61P 35/00
A61P 31/16
A61P 31/04
A61P 3/00
A61P 31/12
A61P 25/24
A61P 25/04
A61P 29/00
A61P 37/08
A61P 15/00
A61P 19/10
A61K 49/00
US Classification:
424 169, 4241581, 424 92, 4241331, 4241351, 4241781
Abstract:
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers

View page
US Patent:
20190367590, Dec 5, 2019
Filed:
Apr 18, 2019
Appl. No.:
16/388184
Inventors:
- LAS VEGAS NV, US
- IOWA CITY IA, US
Ana Recober - Iowa City IA, US
Adisa Kuburas - North Liberty IA, US
Ann C. Raddant - Iowa City IA, US
Brian R. Kovacevich - Snohomish WA, US
John Latham - Seattle WA, US
Jeffrey T.L. Smith - Dublin, IE
Leon F. Garcia-Martinez - Woodinville WA, US
International Classification:
C07K 16/18
Abstract:
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them.

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels

View page
US Patent:
20190240331, Aug 8, 2019
Filed:
Feb 13, 2019
Appl. No.:
16/274985
Inventors:
- Las Vegas NV, US
Eric A. Kaiser - Iowa City IA, US
Ana Recober - Iowa City IA, US
Adisa Kuburas - Iowa City IA, US
Ann C. Raddant - Iowa City IA, US
Brian R. Kovacevich - Snohomish WA, US
John Latham - Seattle WA, US
Jeffrey T.L. Smith - Bellevue WA, US
Leon F. Garcia-Martinez - Woodinville WA, US
International Classification:
A61K 45/06
C07K 16/26
Abstract:
The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels

View page
US Patent:
20180161434, Jun 14, 2018
Filed:
Nov 20, 2017
Appl. No.:
15/818000
Inventors:
- LAS VEGAS NV, US
- Iowa City IA, US
Ana RECOBER - Iowa City IA, US
Adisa KUBURAS - Iowa City IA, US
Ann C. RADDANT - Iowa City IA, US
Brian R. KOVACEVICH - Snohomish WA, US
John LATHAM - Seattle WA, US
Jeffrey T.L. SMITH - Bellevue WA, US
Leon F. GARCIA-MARTINEZ - Woodinville WA, US
International Classification:
A61K 45/06
C07K 16/26
A61K 39/00
Abstract:
The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers

View page
US Patent:
20170342141, Nov 30, 2017
Filed:
Jun 13, 2017
Appl. No.:
15/621105
Inventors:
- LAS VEGAS NV, US
- Iowa City IA, US
Ana Recober - Iowa City IA, US
Adisa Kuburas - North Liberty IA, US
Ann C. Raddant - Iowa City IA, US
Brian R. Kovacevich - Snohomish WA, US
John Latham - Seattle WA, US
Jeffrey T.L. Smith - Dublin 13, GB
Leon F. Garcia-Martinez - Woodinville WA, US
International Classification:
C07K 16/18
A61K 39/00
Abstract:
The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them.
Ann C Raddant from Muskego, WI, age ~38 Get Report